Agenus Announces Updated Phase 1 Data and Progress On BOT/BAL Development In Metastatic MSS Colorectal Cancer, Updated Phase 1 Data Demonstrate 12-Month Overall Survival (OS) Of 71% And 18-Month OS Of 62%
Portfolio Pulse from Benzinga Newsdesk
Agenus has announced updated Phase 1 data showing promising results in metastatic MSS colorectal cancer treatment, with 12-month overall survival at 71% and 18-month at 62%. The company intends to discuss Phase 2 interim results with the FDA and plans to submit these results to a major medical conference in H2 2024.
April 12, 2024 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Agenus reports promising Phase 1 data for metastatic MSS colorectal cancer, with plans to discuss Phase 2 results with the FDA and present at a major conference in 2024.
The positive Phase 1 data and the company's plans to engage with the FDA and present at a major medical conference are likely to be viewed positively by investors, potentially leading to increased investor confidence and a positive impact on AGEN's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100